Key to symbols
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
4.5. Drugs used in the treatment of obesity
4.5.2. Centrally acting appetite suppressants
Total Formulary
LIRAGLUTIDE (Saxenda) (injection)
Restrictions:
Restricted to initiation only on the advice of the Glasgow and Clyde Specialist Weight Management Service as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of BMI ≥35kg/m² (obesity class II and above) with:
- Non-diabetic hyperglycaemia (prediabetes) at high risk of type 2 diabetes which is defined as having either:
- Fasting plasma glucose level of 5.5 to 6.9mmol/L or
- HbA1c of 6.0 to 6.4% (42 to 47mmol/mol), and
- High risk of cardiovascular disease (CVD):
- Total cholesterol >5mmol/L, or
- High-density lipoprotein (HDL) <1.0mmol/L for men and <1.3mmol/L for women, or
- Systolic blood pressure (SBP) >140mmHg
Prescribing Notes:
**Current nationwide supply problem. No new patients should be initiated on Saxenda until supply problem has resolved and a pathway has been agreed and implemented**